HOWL
NASDAQ
US
Werewolf Therapeutics, Inc. - Common Stock
$1.01
▲ +$0.05
(+5.43%)
Vol 403K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$30.8M
ROE
-144.4%
Margin
-578.7%
D/E
93.39
Beta
0.74
52W
$1–$2
Wall Street Consensus
11 analysts · Apr 20265
Strong Buy
4
Buy
2
Hold
0
Sell
0
Strong Sell
81.8%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.35 | $-0.17 | +$0.18 |
| Sep 2025 | $-0.40 | $-0.36 | +$0.04 |
| Jun 2025 | $-0.49 | $-0.40 | +$0.09 |
| Mar 2025 | $-0.40 | $-0.40 | +$0.00 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$16.7M | -$20.4M | -$18.1M | -$18.0M | -$16.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -111.9% | -111.9% | -111.9% | -111.9% | -144.4% | -144.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -578.7% | -578.7% | -578.7% | -578.7% | -578.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 65.37 | 65.37 | 65.37 | 65.37 | 93.39 | 93.39 |
| Current Ratio | 5.30 | 5.30 | 5.30 | 5.30 | 3.87 | 3.87 |
Key Ratios
ROA (TTM)
-71.7%
P/S (TTM)
3.31
P/B
0.9
EPS (TTM)
$-1.62
CF/Share
$-1.04
52W High
$2.38
52W Low
$0.56
$0.56
52-Week Range
$2.38
Financial Health
Free Cash Flow
-$15.2M
Net Debt
-$28.4M
Cash
$65.7M
Total Debt
$37.3M
As of Sep 30, 2025
How does HOWL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
HOWL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.3
▼
74%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
0.9
▼
63%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
HOWL profitability vs Biotechnology peers
ROE
-144.4%
▼
115%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-578.7%
▼
102%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-71.7%
▼
54%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
HOWL financial health vs Biotechnology peers
D/E ratio
93.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.9
▼
13%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.7
▼
24%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
HOWL fundamentals radar
HOWL
Peer median
Industry
HOWL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HOWL vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
EVNIN LUKE BASIL
Director · Jan 16
38782 shs
EVNIN LUKE BASIL
Director · Jan 15
111227 shs
EVNIN LUKE BASIL
Director · Jan 12
91374 shs
EVNIN LUKE BASIL
Director · Jan 07
71054 shs
Last 90 days
Top Holders
Top 5: 22.45%RA Capital Management, L.P.
13.76%
$5.2M
Vanguard Group Inc
2.90%
$1.1M
MPM Bioimpact LLC
2.87%
$1.1M
Bank of America Corporation
1.52%
$569K
Renaissance Technologies, L…
1.40%
$523K
As of Dec 31, 2025
Latest News
No related news yet